Share on StockTwits

Akorn (NASDAQ:AKRX) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued to investors on Monday. The firm currently has a $36.90 price target on the stock. Zacks‘s price objective points to a potential upside of 7.52% from the company’s current price.

Shares of Akorn (NASDAQ:AKRX) traded up 2.10% on Monday, hitting $35.04. 1,073,020 shares of the company’s stock traded hands. Akorn has a one year low of $15.76 and a one year high of $37.55. The stock has a 50-day moving average of $33.32 and a 200-day moving average of $26.79. The company has a market cap of $3.647 billion and a P/E ratio of 84.95.

Akorn (NASDAQ:AKRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.20 by $0.05. The company had revenue of $150.70 million for the quarter, compared to the consensus estimate of $145.16 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s quarterly revenue was up 95.7% on a year-over-year basis. On average, analysts predict that Akorn will post $0.97 earnings per share for the current fiscal year.

In other Akorn news, CEO Rajat Rai unloaded 903,659 shares of Akorn stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $33.62, for a total value of $30,381,015.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of other firms have also recently commented on AKRX. Analysts at Jefferies Group raised their price target on shares of Akorn from $31.00 to $40.00 in a research note on Wednesday, August 6th. Separately, analysts at Piper Jaffray raised their price target on shares of Akorn from $33.00 to $45.00 in a research note on Wednesday, August 6th. They now have an “overweight” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Akorn from $26.00 to $36.00 in a research note on Wednesday, August 6th. They now have a “sector perform” rating on the stock. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $35.30.

Akorn, Inc is a manufacturer and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.